Fig. 3: Impact of somatic mutations identified at diagnosis on PFS according to type of mutations and age groups. | Leukemia

Fig. 3: Impact of somatic mutations identified at diagnosis on PFS according to type of mutations and age groups.

From: Somatic mutations and outcomes in chronic myeloid leukemia adolescent and young adults compared to children, adults, and BCR::ABL1-positive acute lymphoblastic leukemia

Fig. 3

PFS of (A) AYA and (B) adult CML patients with any mutation identified at diagnosis compared to patients with no mutation. Effect of ASXL1 mutations observed at diagnosis on PFS in (C) AYA and (D) adult patients. Hazard R (95% CI) derived from Cox proportional hazard regression models and the p-value calculated by the Log-rank test are shown. The number of patients at risk is shown in tables below. Allmut—patients with any mutation at diagnosis; wt - patients with no mutation during the whole TKI follow-up.

Back to article page